PAGE 2024

InSysBio to take part in PAGE 2024

events

Conference

May 16, 2024

InSysBio announces its participation in the Thirty-second PAGE Meeting which is to be held from 26-28 June, 2024, at the Ergife Hotel in Rome, Italy. InSysBio will conduct a workshop on Immune Response Template (IRT) in frames of the Meeting on June 25, 2024, 11:00 – 14:00 CET. This workshop aims to demonstrate IRT templates export, edition and merge with existing projects for QSP platform development. The workshop is free of charge. Register here

Moreover, InSysBio team is going to present its modeling services & software to optimize drug development at the Booth #15 and 4 posters in frames of the Meeting, namely:

Wednesday, June 26, 10:20-11:50:

I-083 "Exploring strategies to enhance DNAM1 signaling and inhibit the TIGIT/PVRIG axis" by Oleg Demin Jr, Galina Kolesova, Oleg Demin, Dmitry Shchelokov
I-084 "Optimizing first-in-human dose for HPN536, a T-Cell Engager Targeting Mesothelin: comparison of MABEL PK-driven approach and mechanistic translational PK/RO/PA modeling" by Oleg Demin Jr, Galina Kolesova, Dmitry Shchelokov

Thursday, June 27, 09:50-11:20:

III-033 "Cis-binding of bispecific antibodies: effect of additional valency and dose on the antibody-target complexes formation on the example of antibody CTX8371" by Veronika Musatova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin

Wednesday-Friday:

S-03 "Secure and Scalable Computational Environment for Virtual Patients Simulations" by Ivan Borisov, Evgeny Metelkin

Check out our Booth #15 and join our workshop at PAGE 2024!

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com

←	December 2019	→
Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3 1. 03 Dec 2019 15:35 InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Upcoming Events

Mo	Tu	We	Th	Fr	Sa	Su
←	December 2019					→
						1
2	3 1. 03 Dec 2019 15:35 InSysBio QSP model for BTK inhibitors will be presented at the 61 ASH Annual Meeting QSP model of BTK inhibitors developed by InSysBio in collaboration with BeiGene will be presented as a poster by Srikumar Sahasranaman from Beigene at 61st American Society of Hematology (ASH) Annual Meeting & Exposition. The model describes marketed BTK inhibitors (ibrutinib and acalabrutinib) and zanubrutinib, a BTK inhibitor which recently received accelerated approval from the FDA as a treatment for mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy.	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31